Overview

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
0
Participant gender:
All
Summary
Inactivation of the FAAH (Fatty Acid Amide Hydrolase) enzyme has been shown to relieve pain and inflammation in animal studies. PF-04457845 has been shown to inactivate the FAAH enzyme in animals and healthy human volunteers. The purpose of this study is to evaluate whether PF-04457845 can inactivate the FAAH enzyme in patients experiencing pain due to OA and whether this results in these patients experiencing less pain.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Naproxen
Criteria
Inclusion Criteria:

- Subjects must have a diagnosis of Osteoarthritis (OA) of the knee confirmed by X-ray

- Subjects must be willing and able to stop all current pain therapy for the duration of
study. (Limited and specific pain therapy will be available throughout the study)

- Subjects can be male or female between the ages of 18 and 75 years inclusive, but
female subjects must not be able become pregnant

Exclusion Criteria:

- Subjects must not have any condition or medical history that might interfere with
their ability to complete the study assessments